arrow Log In to View Account     |      
HOME
Johns Hopkins Medicine
Hopkins Logo



Presented by the Johns Hopkins University School of Medicine.

This educational activity is supported by an educational grant from Alimera Sciences, Inc.

OVERVIEW

Diabetic macular edema (DME) is the major cause of vision loss in people with diabetic retinopathy. In recent years, results from several clinical trials have been published including the Diabetic Retinopathy Clinical Research Network’s “Protocol H” trial, the READ-2 trial, the RESOLVE trial, “Protocol I” trial, RESTORE, and FAME. Furthermore, new delivery system technology has been developed and is being introduced into the armamentarium of clinical practice. Results from several studies assessing the safety and efficacy of steroids using different delivery methods for the management of DME have been recently announced and even more will be announced in the near future. In addition to steroids, results from trials using laser therapy, vascular endothelial growth factor (VEGF) inhibitors and other approaches are breaking into clinical practice. With all these emerging opportunities for DME, it is incumbent on the ophthalmologist to remain well informed and aggressive with rapid diagnosis and optimal treatment.

GOAL

The goal of this activity is to narrow professional practice gaps on the topic of DME by providing retina specialists and comprehensive ophthalmologists with the most current knowledge and strategies to improve patient outcomes.

TARGET AUDIENCE

This activity is designed for retina specialists and comprehensive ophthalmologists. No prerequisites required.

LEARNING OBJECTIVES

After completing this activity, the participant will demonstrate the ability to:

  • ANALYZE the safety and efficacy of ophthalmic preparations used to manage DME.
  • EVALUATE the results of the latest clinical trials for the management of DME to determine best practices.

The Johns Hopkins University School of Medicine takes responsibility for the content, quality, and scientific integrity of this CME activity.

ACCREDITATION STATEMENT

The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

The Johns Hopkins University School of Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

After reviewing this online activity, participants may receive credit by completing the CME test, evaluation, and receiving a score of 70% or higher. A certificate of participation will be available online immediately following successful completion of the activity.

The estimated time to complete this activity: 1.5 hours.

Release date: June 15, 2012. Expiration date: June 15, 2014.

Full Disclosure Policy Affecting CME Activities
As a provider approved by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the Johns Hopkins University School of Medicine Office of Continuing Medical Education (OCME) to require signed disclosure of the existence of financial relationships with industry from any individual in a position to control the content of a CME activity sponsored by OCME. Members of the Planning Committee are required to disclose all relationships regardless of their relevance to the content of the activity. Faculty are required to disclose only those relationships that are relevant to their specific presentation. The following relationships have been reported for this activity:

Chair and Planner
Peter A. Campochiaro, MD

Eccles Professor of Ophthalmology and Neuroscience
Johns Hopkins University School of Medicine
Baltimore, Maryland

Participating Faculty
David Antonetti, PhD

Professor, Departments of Ophthalmology and Visual Sciences and Molecular and Integrative Physiology
Jules and Doris Stein Professorship in Ophthalmology
Kellogg Eye Center
University of Michigan
Ann Arbor, Michigan

Baruch D. Kuppermann, MD, PhD
Professor and Chief, Retina Service
Vice-Chair, Clinical Research
Department of Ophthalmology
The Gavin Herbert Eye Institute
Irvine, California

Dante J. Pieramici, MD (Planner)
Ophthalmologist
California Retina Consultants
Santa Barbara, California

Participating Faculty Disclosures
Dr Campochiaro reports serving as a consultant/advisor for Allergan, Inc, Genentech, Inc, GlaxoSmithKline, and LPath, Inc; receiving grants/research funding from Alcon Laboratories, Inc, Alimera Sciences, Genentech, Inc, Genzyme Corporation, GlaxoSmithKline, and Oxford Biomedica; and serving on the Data and Safety Monitoring Committee/Board for Advanced Cell Technology, Inc and Regeneron Pharmaceuticals, Inc.

Dr Kuppermann reports Reports receiving research/grants support from and serving as a consultant for Alimera Sciences and Allergan, Inc.

Dr Pieramici reports serving as a consultant for Alimera Sciences and Genentech, Inc; and receiving grant/research support from Genentech, Inc.

No other speakers have indicated that they have any financial interests or relationships with a commercial entity.

Planner Disclosures
Dr Campochiaro reports serving as a consultant/advisor for Allergan, Inc, Genentech, Inc, GlaxoSmithKline, and LPath, Inc; receiving grants/research funding from Alcon Laboratories, Inc, Alimera Sciences, Genentech, Inc, Genzyme Corporation, GlaxoSmithKline, and Oxford Biomedica; and serving on the Data and Safety Monitoring Committee/Board for Advanced Cell Technology, Inc and Regeneron Pharmaceuticals, Inc.

Dr Pieramici reports serving as a consultant for and receiving honoraria from Alimera Sciences, Genentech, Inc, and Thrombogenics; and receiving grant/research support from Genentech, Inc.

No other planners have indicated that they have any financial interests or relationships with a commercial entity.

Note: Grants to investigators at The Johns Hopkins University are negotiated and administered by the institution that receives the grants, typically through the Office of Research Administration. Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor, but may receive salary or other support from the institution to support their effort on the project(s).

Off-Label Product Discussion

The following faculty members have disclosed that their presentation will reference unlabeled/unapproved use of drugs or products:

David Antonetti, PhD: Data on the mechanism of action of glucocorticoids such as dexamethasone and the protein kinase C inhibitor ruboxistaurin in preclinical studies in cell culture and rodents.

Peter A. Campochiaro, MD: Bevacizumab and triamcinolone.

Baruch D. Kuppermann, MD, PhD: Fluocinolone acetonide intravitreal implant, sustained-release fluocinolone acetonide, triamcinolone formulations.

Dante J. Pieramici, MD: Bevacizumab.

DISCLAIMER

The opinions and recommendations expressed by faculty and other experts whose input is included in this program are their own. This handout is produced for educational purposes only. Use of Johns Hopkins University School of Medicine name implies review of educational format, design, and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects before administering pharmacologic therapy to patients.

INTERNET CME POLICY

The Office of Continuing Medical Education (CME) at the Johns Hopkins University School of Medicine is committed to protect the privacy of its members and customers. Johns Hopkins University SOM CME maintains its Internet site as an information resource and service for physicians, other health professionals, and the public. Continuing Medical Education at the Johns Hopkins University School of Medicine will keep your personal and credit information confidential when you participate in a CME Internet based activity. Your information will never be given to anyone outside of the Johns Hopkins University School of Medicine’s CME activity. CME collects only the information necessary to provide you with the services that you request.

CONFIDENTIALITY DISCLAIMER FOR CME ACTIVITY PARTICIPANT

I certify that I am participating in this Johns Hopkins University School of Medicine activity for CME-accredited training and/or educational purposes.

I understand that while I am participating in this capacity, I may be exposed to "protected health information," as that term is defined and used in Johns Hopkins policies and in the federal HIPAA privacy regulations (the "Privacy Regulations"). Protected health information is information about a person’s health or treatment that identifies the person. I also understand that while I am participating in this capacity I will be treated as a temporary member of Johns Hopkins for purposes of the Privacy Regulations only.

I pledge and agree to use and disclose any of this protected health information only for the training and/or educational purposes of my visit and to keep the information confidential.

I understand that I may direct to the Johns Hopkins Privacy Officer any questions I have about my obligations under this Confidentiality Pledge or under any of the Hopkins policies and procedures and applicable laws and regulations related to confidentiality. The contact information is: Johns Hopkins Privacy Officer, telephone: 410-735-6509, e-mail: HIPAA@jhmi.edu.

“The Office of Continuing Medical Education at the Johns Hopkins University School of Medicine, as sponsor of this activity, has relayed information with the CME attendees/participants and certify that the visitor is here for training, education and/or observation purposes only.”

Johns Hopkins University School of Medicine
Office of Continuing Medical Education
720 Rutland Avenue/ Turner 20
Baltimore, Maryland 21205-2195
Reviewed & Approved by: General Counsel, Johns Hopkins Medicine (4/1/09)

HARDWARE AND SOFTWARE REQUIREMENTS

Pentium 800 processor or greater, Windows 98/NT/200/XP or Mac OS 9/X or later, Microsoft Internet Explorer, Safari, Firefox, Windows Media Player 9.0 or later Flash player, 128 MB of RAM Monitor settings: High color at 800 x 600 pixels, sound card and speakers, Adobe Acrobat Reader.

ACTIVITY CONTENTS
Please complete the pre-test; view the following presentation and respond to the interactive questions; and complete the post-test and evaluation to receive CME credit for this activity.

Pre-Test

Conference Goals
Peter A. Campochiaro, MD

Overview of Diabetic Macular Edema and Strategies for Treatment
David Antonetti, PhD

Anti-VEGF Clinical Update
Dante J. Pieramici, MD

Steroid Clinical Update
Baruch D. Kuppermann, MD, PhD

Practical “What Would You Do?” Session and Q&A
Moderated by Peter A. Campochiaro, MD

Post-Test
procced to pretest
footer